Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Sharp & Dohme LLC | 1,344 |
| 2 | Takeda Pharmaceutical Co Ltd | 1,105 |
| 3 | Ono Pharmaceutical Co Ltd | 1,007 |
| 4 | Boehringer Ingelheim International GmbH | 447 |
| 5 | Organon Pharma UK Ltd | 407 |
| 6 | Gilead Sciences Inc | 365 |
| 7 | Samsung Display Co Ltd | 324 |
| 8 | MedImmune Ltd | 311 |
| 9 | F Hoffmann La Roche AG | 289 |
| 10 | Janssen Pharmaceutica NV | 281 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C07D | Heterocyclic compounds | 22,803 |
| 2 | A61P | Therapeutic activity (drug indications) | 22,308 |
| 3 | A61K | Medicinal preparations | 14,236 |
| 4 | C07C | Acyclic and carbocyclic compounds | 2,990 |
| 5 | C07F | Organometallic compounds | 1,977 |
| 6 | C07K | Peptides | 1,200 |
| 7 | Y02A | Climate change adaptation | 915 |
| 8 | C07B | General methods of organic chemistry | 874 |
| 9 | A01N | Preservation of bodies; biocides; pest repellents | 853 |
| 10 | Y02P | Climate change mitigation: production | 711 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Tetrahydropyridine oxime compounds | 1990 | Warner Lambert Co LLC | 72 |
| O-substituted tetrahydropyridine oxime cholinergic agents | 1987 | Warner Lambert Co LLC | 72 |
| 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | 2008 | AstraZeneca AB | 66 |
| Thieno tetrahydropyridines useful as class III antiarrhythmic agents | 1994 | Ortho Pharmaceutical Corp | 64 |
| 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | 2008 | AstraZeneca AB | 57 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Diabetes Treatment and Management | 23 |
| 2 | Neuropeptides and Animal Physiology | 21 |
| 3 | Forensic Toxicology and Drug Analysis | 19 |
| 4 | Hepatitis C virus research | 16 |
| 5 | Neuroscience and Neuropharmacology Research | 14 |
| 6 | Neurotransmitter Receptor Influence on Behavior | 12 |
| 7 | Nitric Oxide and Endothelin Effects | 12 |
| 8 | NF-κB Signaling Pathways | 9 |
| 9 | Pain Mechanisms and Treatments | 8 |
| 10 | Peptidase Inhibition and Analysis | 7 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Kenner C. Rice | National Institute on Drug Abuse | 36 |
| 2 | James E. Foley | Novartis (United States) | 35 |
| 3 | Anja Schweizer | Novartis (Switzerland) | 32 |
| 4 | Fiona McPhee | Bristol-Myers Squibb (United States) | 29 |
| 5 | Hemendra N. Bhargava | University of Illinois Chicago | 20 |
| 6 | Kazuaki Chayama | Hiroshima University | 19 |
| 7 | David M. Pollock | Augusta University | 17 |
| 8 | Federico Mensa | AbbVie (United States) | 17 |
| 9 | Bo Åhrén | Lund University | 15 |
| 10 | Hiromitsu Kumada | Toranomon Hospital | 15 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields | 2009 | 7619 | Protein Structure and Dynamics |
| Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. | 1994 | 2221 | Nitric Oxide and Endothelin Effects |
| Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele | 2019 | 2164 | Asthma and respiratory diseases |
| Therapeutic siRNA: state of the art | 2020 | 1537 | MicroRNA in disease regulation |
| Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. | 1992 | 1522 | Immune Response and Inflammation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of pyrrolidines?
Which companies hold the most patents on pyrrolidine compounds?
What research topics are most associated with pyrrolidines in academic literature?
How extensive is the intellectual property and academic coverage for pyrrolidines?
What were some early significant patent applications for tetrahydropyridine compounds?